Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q4 FY2019 Earnings Presentation
12 slides from Morepen Laboratories's earnings presentation, May 6, 2019
Slide 1: Exchange filing cover letter: Investor Presentation
... .....~ IAO~E~EN Date: 06/05/2019 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street Mumbai- 400 001 Tel No: (022) 26598100- 8114 Phones: 91-22-22721233/4 Fax No: (022) 26598120 Fax: 91
Slide 2: Investors Presentation for Q4'FY19 - May 2019
I CHOOSE INVESTORS PRESENTATION FOR Q4’FY19 - MAY 2019
Slide 3: Disclaimer
Disclaimer: This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied forward looking
Slide 4: Highlights of Q4'FY19 Performance
Highlights of Q4’FY19 Performance • Standalone total revenue at 207 cr. for Q4’FY19 is up by 31% from Q4’FY18 and the Consolidated total revenue is up by 28% at Rs. 220 cr. for the corresponding period registering excellent growth in all business segments. 31% • Export Revenue in Q4’FY19 is up by 51
Slide 5: All Around Growth
All Around Growth ₹ crores • Overall Standalone revenue at Rs.207.10 Crores has recorded 31% jump in Q4’FY19 as compared to Q4’FY18. Standalone Quarterly Revenue • API (Active Pharmaceuticals Ingredients) business with revenue share of 62% recorded a growth of 34% in Q4’FY19 against same 207.10 quar
Slide 6: APIs: Sparking Growth
APIs: Sparking Growth ₹ crores • Overall API business at Rs. 125.48 Crores has shown a remarkable API Revenues growth of of 34% in Q4’FY’19. 125.48 • Finished APIs have registered a growth of 24% at Rs. 111.03 Crores in 34% Q4’FY19 as against Q4’FY18. • API Exports at Rs. 95.41 Crores have a sharp u
Slide 7: Devices Business - Growth Driver
Devices Business - Growth Driver ₹ crores • Home Diagnostic portfolio has been growing at fast pace and has recorded a growth of 35% in FY19 at Rs. 140 Crores from FY18 riding Diagnostics Devices Revenues its success story. 27.77 • Blood Gluco Monitors sales have marked an excellent growth of 43% 12
Slide 8: Finished Dosages: High Growth
Finished Dosages: High Growth ₹ crores • Finished Dosages has recorded substantial growth of 30% in Finished Dosages Revenues Q4’FY19 at Rs. 49.35 Crores as compared to Q4’FY18. • Branded Prescription (Rx) products sale revenue has grown up during 30% 49.35 the Q4’FY19 20% from FY18. • Branded gener
Slide 9: Phenomenal Performance in Q4'FY19
Phenomenal Performance in Q4’FY19 ₹ crores • There is an increase of 31% in Net Revenue in Q4’FY19 as compared to Q4’FY18 on Standalone basis. Quarterly Net Revenues • EBIDTA for the Q4’FY’19 has jumped by 45% from Rs.14.59 Crores 207.10 in Q4’FY18 to Rs. 21.09 Crores for the quarter. 31% • Cash Sur
Slide 10: Debt Free Company
Debt Free Company ₹ crores Zero Outstanding Debt • The Company has repaid its all its outstanding loans and is now a Debt Free 47 Company. • There is no outstanding loan liability on the company either on account of Term loan or Working capital facility as per CDR. • The company had peak outstanding
Slide 11: Synopsis of Q4'FY19 Performance
Synopsis of Q4’FY19 Performance ₹ crores Standalone Standalone Growth Consolidated (17-18) (18-19) %age (18-19) Net Revenue 158.34 207.10 31% 219.74 Expenditure 143.75 186.01 29% 196.97 EBIDTA 14.59 21.09 45% 22.78 Interest 0.72 0.92 29% 0.93 Cash Surplus 13.87 20.17 45% 21.85 Dep. & Amortization 9.
Slide 12: Thank You
Tran You By MOREPEN ‘The Joy Of Growing Together
Morepen Laboratories — Q4 FY2019 Earnings Presentation on 6ix